Generate a tailored SOP for Dr. Markus Siegelin. Improve your application with a focused, well-structured draft.
Markus D. Siegelin, MD, is an Associate Professor in the Department of Pathology and Cell Biology at Columbia University Irving Medical Center. His research focuses on understanding the mechanisms of cell death in tumors to develop novel treatment strategies. Dr. Siegelin’s work is particularly centered on glioblastoma, a common and aggressive brain tumor. He investigates the Warburg effect, a metabolic phenomenon observed in malignant tumors, which involves increased glucose utilization and lactate production. His research demonstrates that certain FDA-approved histone deacetylase inhibitors can disrupt super-enhancers, contributing to metabolic reprogramming in glioblastoma cells. Moreover, he has uncovered significant findings related to the IDH1 mutation, showing that targeting Bcl-xL can enhance apoptosis in gliomas. Dr. Siegelin has published numerous papers in high-impact journals and has played a vital role in initiating clinical trials based on his lab findings. His research aims to improve therapies for glioblastoma and solid malignancies by addressing metabolic resistance and identifying effective drug combinations.
Columbia University Irving Medical Center • New York, NY
Associate Professor in Pathology and Cell Biology, focusing on glioblastoma research.
Columbia University Medical Center • New York, NY
Research on cell death mechanisms in tumors and therapeutic resistance.
Department of Anthropology (GSAS)